Matinas BioPharma Holdings, Inc. (MTNB)
NYSEAMERICAN: MTNB · Real-Time Price · USD
0.596
-0.014 (-2.31%)
Apr 28, 2026, 4:00 PM EDT - Market closed
MTNB Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | - | - | 1.1 | 3.19 | 0.03 | Upgrade
|
| Revenue Growth (YoY) | - | - | -65.62% | 9560.61% | -79.16% | Upgrade
|
| Cost of Revenue | 0.09 | 11.43 | 14.49 | 16.68 | 14.58 | Upgrade
|
| Gross Profit | -0.09 | -11.43 | -13.39 | -13.49 | -14.55 | Upgrade
|
| Selling, General & Admin | 6.88 | 8.73 | 10.37 | 11.1 | 10.19 | Upgrade
|
| Operating Expenses | 6.88 | 8.73 | 10.37 | 11.1 | 10.19 | Upgrade
|
| Operating Income | -6.96 | -20.16 | -23.77 | -24.59 | -24.74 | Upgrade
|
| Interest Expense | -0 | -0 | -0 | -0 | -0 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.26 | 0.26 | 0.83 | 3.59 | 1.46 | Upgrade
|
| EBT Excluding Unusual Items | -7.22 | -19.9 | -22.94 | -21 | -23.28 | Upgrade
|
| Impairment of Goodwill | - | -2.09 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.04 | - | - | - | - | Upgrade
|
| Asset Writedown | - | -2.34 | - | - | - | Upgrade
|
| Other Unusual Items | -3.16 | - | - | - | - | Upgrade
|
| Pretax Income | -10.35 | -24.33 | -22.94 | -21 | -23.28 | Upgrade
|
| Income Tax Expense | - | -0.08 | - | - | - | Upgrade
|
| Net Income | -10.35 | -24.25 | -22.94 | -21 | -23.28 | Upgrade
|
| Preferred Dividends & Other Adjustments | 0.62 | - | - | - | 0.4 | Upgrade
|
| Net Income to Common | -10.96 | -24.25 | -22.94 | -21 | -23.68 | Upgrade
|
| Shares Outstanding (Basic) | 5 | 5 | 4 | 4 | 4 | Upgrade
|
| Shares Outstanding (Diluted) | 5 | 5 | 4 | 4 | 4 | Upgrade
|
| Shares Change (YoY) | 12.50% | 11.98% | 0.21% | 3.16% | 6.75% | Upgrade
|
| EPS (Basic) | -2.00 | -4.98 | -5.28 | -4.84 | -5.63 | Upgrade
|
| EPS (Diluted) | -2.00 | -4.98 | -5.28 | -4.84 | -5.63 | Upgrade
|
| Free Cash Flow | -7.01 | -15.89 | -15.5 | -20.05 | -15.48 | Upgrade
|
| Free Cash Flow Per Share | -1.28 | -3.27 | -3.57 | -4.62 | -3.68 | Upgrade
|
| Operating Margin | - | - | -2168.43% | -771.33% | -74954.54% | Upgrade
|
| Profit Margin | - | - | -2093.25% | -658.63% | -71754.54% | Upgrade
|
| Free Cash Flow Margin | - | - | -1413.87% | -628.86% | -46918.18% | Upgrade
|
| EBITDA | -6.92 | -19.79 | -23.37 | -24.23 | -24.46 | Upgrade
|
| D&A For EBITDA | 0.04 | 0.37 | 0.39 | 0.36 | 0.28 | Upgrade
|
| EBIT | -6.96 | -20.16 | -23.77 | -24.59 | -24.74 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.